TEVA : Summary for Teva Pharmaceutical Industries - Yahoo Finance

U.S. Markets close in 13 mins.

Teva Pharmaceutical Industries Limited (TEVA)


NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
31.59+0.47 (+1.49%)
As of 3:47PM EDT. Market open.
People also watch
MYLNVSGILDAMGNABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close31.13
Open31.41
Bid0.00 x
Ask0.00 x
Day's Range31.40 - 31.92
52 Week Range30.57 - 57.41
Volume5,775,393
Avg. Volume9,121,561
Market Cap32.2B
Beta0.56
PE Ratio (TTM)451.36
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.36 (4.23%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Dividend Stocks That Retirees Should Avoid
    Motley Fool2 days ago

    3 Dividend Stocks That Retirees Should Avoid

    High dividend yields for CenturyLink, GlaxoSmithKline, and Teva look great, but there's more to the story for these stocks.

  • Reuters4 days ago

    Teva's new asthma inhaler poses first competition for GSK's Advair

    Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. Teva, which won U.S. approval in January to make an inhaler similar to Advair, also launched a generic version of its own inhaler, AirDuo RespiClick. AirDuo is not a true generic of Advair, but contains the same two active ingredients, fluticasone propionate and salmeterol.

  • Business Wire4 days ago

    Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol

    Teva Pharmaceutical Industries Ltd., today announced the simultaneous launch of AirDuo™ RespiClick® inhalation powder and its authorized generic for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist combination.